ClinicalTrials.gg
CompletedNCT03116347Updated Jan 11, 2023Results posted

Post-Authorization Safety, Tolerability and Immunogenicity Evaluation of HyQvia in Pediatric PIDD Subjects

A Phase 4 interventional study of HYQVIA and KIOVIG in Primary Immunodeficiency Diseases (PID), sponsored by Baxalta now part of Shire. Completed at 20 sites in 8 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2023-01-11.

Sponsored by Baxalta now part of Shire (part of Takeda) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
42
Allocation
Non-randomized
Ages
2 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies testing Immunoglobulin G in Primary Immunodeficiency Diseases — 2 open to participants now, 4 under way, 4 of them phase 3. Immunoglobulin G · Primary Immunodeficiency Diseases.

Enrollment
16th of 28
42 · median 45
Started
2017
with 2 others
Phase 4
3 of 29
none open now
Registered
21st of 29
by date
Lead sponsor
9 of 29
Baxalta now part of Shire

Among the 29 studies testing Immunoglobulin G in Primary Immunodeficiency Diseases, this one is the 16th largest by enrollment of the 28 interventional ones that give a count, is one of 3 that started in 2017, is one of 3 in phase 4, and was the 21st registered.

Primary Immunodeficiency Diseases

211 studies on the registry are indexed under Primary Immunodeficiency Diseases; 51 are open to participants now.

Browse Primary Immunodeficiency Diseases studies →

Open to participants now

2 of the 29 studies testing Immunoglobulin G in Primary Immunodeficiency Diseases are open now. Recruiting first, the newest first:

All 2 open studies →

About Immunoglobulin G

Immunoglobulin G: first FDA approval 1944 (Baygam, Gamastan S/D), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 35 Primary Immunodeficiency Diseases studies recruiting now, 12 (34%) set no upper age limit and 10 (29%) stop at 75 or younger; 28 take children under 18; 11 take healthy volunteers.

This study: 2 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing Immunoglobulin G in Primary Immunodeficiency Diseases, or all of them as a file.
02

Study summary

The purpose of the study is to acquire additional data on safety, tolerability and immunogenicity of HyQvia in pediatric (age two to \<18 years) patients with Primary Immunodeficiency Diseases (PIDD)

03

Conditions studied

  • Primary Immunodeficiency Diseases (PID)
04

Who can participate

Ages eligible
2 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant must have a documented diagnosis of a form of primary humoral immunodeficiency involving a defect in antibody formation and requiring gammaglobulin replacement, as defined according to the International Union of Immunological Societies (IUIS) Scientific Committee 2015 prior to enrollment. The diagnosis must be confirmed by the sponsor´s Medical Director prior to first treatment with product (IP) in the study.
  2. Participant is at least two and below 18 years of age at the time of screening.
  3. Participant has been receiving a consistent dose of Immunoglobulin G (IgG), administered in compliance with the respective product information for a period of at least three months prior to screening. The average minimum pre-study dose over that interval was equivalent to 300 mg/kg body weight (BW)/four weeks and a maximum dose equivalent to 1000 mg/kg BW/4 weeks.
  4. Participant has a serum trough level of IgG > 5 g/L at screening.
  5. If female of , participant presents with a negative pregnancy test and agrees to employ adequate measures for the duration of the study.
  6. Participant /legally authorized representative is willing and able to comply with the requirements of the protocol.

Exclusion criteria

Exclusion Criteria:

  1. Participant has a known history of or is positive at screening for one or more of the following: surface antigen (HBsAg), polymerase chain reaction (PCR) for virus (HCV), PCR for (HIV) Type 1/2.
  2. Abnormal laboratory values at screening meeting any one of the following criteria (abnormal tests may be repeated once to determine if they are persistent):

    1. Persistent (ALT) and aspartate amino transferase (AST) >2.5 times the (ULN) for the testing laboratory
    2. Persistent severe neutropenia (defined as an [ANC] ≤ 500/mm\^3)
  3. Participant has anemia that would preclude phlebotomy for laboratory studies, according to standard practice at the site.
  4. Participant has an ongoing history of or persistent reactions (urticaria, breathing difficulty, severe hypotension, or anaphylaxis) following intravenous (IV) immunoglobulin, subcutaneous (SC) immunoglobulin, and/or Immune Serum Globulin (ISG) infusions.
  5. Participant has severe immunoglobulin A (IgA) deficiency (\< 7.0 mg/dL) with known anti-IgA antibodies and a history of hypersensitivity. .
  6. Participant has a known allergy to hyaluronidase.
  7. Participant has active infection and is receiving antibiotic therapy for the treatment of infection at the time of screening.
  8. Participant has a bleeding disorder or a count \< 20,000/μL, or who, in the opinion of the investigator, would be at significant risk of increased bleeding or bruising as a result of SC therapy.
  9. Participant has severe dermatitis that would preclude adequate sites for safe product administration in the opinion of the investigator.
  10. Participant has participated in another clinical study involving an IP or device within 30 days prior to enrollment or is scheduled to participate in another clinical study involving an IP or investigational device during the course of this study.
  11. Participant is a family member or employee of the investigator.
  12. If female, participant is pregnant or lactating at the time of enrollment.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    EPOCH 1

    Ramp up period for participants who were not treated with HyQvia prior to this study

    Biological: HYQVIA

  • Experimental
    EPOCH 2

    Participants who were treated with HyQvia prior to this study, and those who completed the ramp up period (Epoch 1). After one year in Epoch 2, participants with anti-rHuPH20 antibody titer \<160 at all time-points during the study will complete the study termination/completion visit at the next possible occasion. Participants with anti-rHuPH20 antibody titer \>=160 during the study and/or at the last measurement will continue for an additional two years of HyQvia treatment and observation.

    Biological: HYQVIA

  • Experimental
    Epoch 3

    Safety follow-up for participants whose anti-rHuPH20 antibody titer was \>= 160 during Epoch 1 or Epoch 2 and who experience either a related serious adverse event (SAE) or a related severe adverse event (AE)

    Biological: KIOVIG · Biological: Cuvitru

Interventions

  • BiologicalHYQVIA

    Drug pages: Immunoglobulin G · Hyaluronoglucosaminidase

    Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase (IGI, 10% with rHuPH20)

    Also known as: IGI 10% with rHuPH20

  • BiologicalKIOVIG

    100 mg/ml solution for Immune Globulin Intravenous Infusion

    Also known as: IGIV 10%, IGI 10%

  • BiologicalCuvitru

    200 mg/ml solution for Immune Globulin Subcutaneous Injection

    Also known as: IGSC 20%, IGI 20%

06

What researchers measure

Primary outcomes

  1. Safety: Number of Participants With Any Severe Related Treatment-emergent Adverse Events (TEAEs) Per Infusion (Excluding Infections)

    An Adverse Event (AE) was defined as any untoward medical occurrence in a participant administered an investigational product (IP) that does not necessarily have a causal relationship with the treatment. TEAEs were the AEs with onset after date-time of first dose of IP, or any medical condition present prior to the start of IP but increased in severity or relationship after date-time of first dose of IP. TEAEs that were recorded as "possibly related" or "probably related" to HYQVIA were considered HYQVIA-related adverse events. Number of participants with any severe related TEAEs (excluding infections) was reported.

    Time frame: From start of study drug administration up to 20 months

  2. Safety: Rate of Any Severe Related TEAEs Per Infusion (Excluding Infections)

    An AE was defined as any untoward medical occurrence in a participant administered an IP that does not necessarily have a causal relationship with the treatment. TEAEs were the AEs with onset after date-time of first dose of IP, or any medical condition present prior to the start of IP but increased in severity or relationship after date-time of first dose of IP. TEAEs that were recorded as "possibly related" or "probably related" to HYQVIA were considered HYQVIA-related adverse events. Severe related TEAEs rate per infusion was calculated as number of severe related TEAEs/total number of infusions administered to participants in the analysis set. Rate of any severe related TEAEs per infusion (excluding infections) was reported.

    Time frame: From start of study drug administration up to 20 months

  3. Safety: Number of Participants With Any Related Serious TEAEs Per Infusion (Excluding Infections)

    TEAEs were the AEs with onset after date-time of first dose of IP, or any medical condition present prior to the start of IP but increased in severity or relationship after date-time of first dose of IP. A serious TEAE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs that were recorded as "possibly related" or "probably related" to HYQVIA were considered HYQVIA-related adverse events. Number of participants with any related serious TEAEs per infusion (excluding infections) was reported.

    Time frame: From start of study drug administration up to 20 months

  4. Safety: Rate of Any Related Serious TEAEs Per Infusion (Excluding Infections)

    TEAEs were the AEs with onset after date-time of first dose of IP, or any medical condition present prior to the start of IP but increased in severity or relationship after date-time of first dose of IP. A serious TEAE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged in-patient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs that were recorded as "possibly related" or "probably related" to HYQVIA were considered HYQVIA-related adverse events. Rate of related serious TEAEs per infusion was calculated as number of related serious TEAEs/total number of infusions administered to participants in the analysis set. Rate of any related serious TEAEs per Infusion (excluding infections) was reported.

    Time frame: From start of study drug administration up to 20 months

Secondary outcomes

  1. Efficacy: Change From Baseline in Total Serum Trough Levels of Immunoglobulin G (IgG) at Month 12

    Change from baseline in total serum trough levels of IgG in Epoch 1 and 2 was reported. Baseline was defined as the last non-missing value before the initial dose of HYQVIA.

    Time frame: Baseline, Month 12

  2. Efficacy: Change From Baseline in Serum Trough Levels of IgG Subclasses at Month 12

    Change from baseline in Serum trough levels of IgG subclasses 1, 2, 3, and 4 in Epoch 1 and 2 was reported. Baseline was defined as the last non-missing value before the initial dose of HYQVIA.

    Time frame: Baseline, Month 12

  3. Efficacy: Change From Baseline in Trough Levels of Specific Antibodies to Clostridium Tetani Toxoid IgG at Month 12

    Change from baseline in trough levels of specific antibodies in clostridium tetani toxoid IgG at Month 12 was reported. Baseline was defined as the last non-missing value before the initial dose of HYQVIA. Here, IU/ml was defined as "International units per milliliter".

    Time frame: Baseline, Month 12

  4. Efficacy: Change From Baseline in Trough Levels of Specific Antibodies to Hepatitis B Virus (HBV) at Month 12

    Change from baseline in trough levels of specific antibodies in HBV at Month 12 was reported. Baseline was defined as the last non-missing value before the initial dose of HYQVIA.

    Time frame: Baseline, Month 12

  5. Efficacy: Change From Baseline in Trough Levels of Specific Antibodies to Haemophilus Influenzae B IgG at Month 12

    Change from baseline in trough levels of specific antibodies in Haemophilus influenzae B IgG at Month 12 was reported. Baseline was defined as the last non-missing value before the initial dose of HYQVIA.

    Time frame: Baseline, Month 12

  6. Safety: Percentage of Participants Who Achieved a Treatment Interval of Three or Four Weeks in Epoch 2

    Percentage of participants who achieved a treatment interval of three or four weeks in Epoch 2 was reported.

    Time frame: Up to 20 months

  7. Safety: Percentage of Participants Who Maintained a Treatment Interval of Three or Four Weeks in Epoch 2 up to 12 Months

    Percentage of participants who maintained a treatment interval of three or four weeks in Epoch 2 up to 12 months was reported.

    Time frame: Up to 12 months

  8. Safety: Number of Participants With Local TEAEs (Excluding Infections)

    TEAEs were the AEs with onset after date-time of first dose of IP, or any medical condition present prior to the start of IP but increased in severity or relationship after date-time of first dose of IP. Number of Participants with local TEAEs (excluding infections) was reported.

    Time frame: From start of study drug administration up to 20 months

  9. Safety: Rate of Local TEAEs Per Infusion (Excluding Infections)

    Rate of local TEAEs per infusion was calculated as number of local adverse events/total number of infusions administered to participants in the analysis set. Only events are included which start prior to participants start date of non-response. Rate of local TEAEs per infusion (excluding infections) was reported.

    Time frame: From start of study drug administration up to 20 months

  10. Safety: Number of Participants With Local Adverse Reaction (Excluding Infections)

    Adverse reaction was defined as any TEAE that meets any of the following criteria: 1) A TEAE considered by either the investigator and/or the sponsor to be possibly or probably related to IP administration, or; 2) A TEAE that begins during infusion of IP or within 72 hours following the end of IP infusion, or; 3) A TEAE for which causality assessment is missing or indeterminate. Number of participants with local adverse reactions (excluding infections) was reported.

    Time frame: From start of study drug administration up to 20 months

  11. Safety: Rate of Local Adverse Reaction Per Infusion (Excluding Infections)

    Rate of local adverse reaction per infusion was calculated as number of local adverse reaction events/total number of infusions administered to participants in the analysis set. Rate of local adverse reactions per infusion (excluding infections) was reported.

    Time frame: From start of study drug administration up to 20 months

  12. Safety: Number of Participants With Systemic TEAEs (Excluding Infections)

    TEAEs were the AEs with onset after date-time of first dose of IP, or any medical condition present prior to the start of IP but increased in severity or relationship after date-time of first dose of IP. Number of participants with systemic TEAEs (excluding infections) was reported..

    Time frame: From start of study drug administration up to 20 months

  13. Safety: Rate of Systemic TEAEs Per Infusion (Excluding Infections)

    Rate of systemic TEAEs per infusion was calculated as number of systemic adverse events/total number of infusions administered to participants in the analysis set. Rate of systemic TEAEs per infusion was assessed based on events per infusion.

    Time frame: From start of study drug administration up to 20 months

  14. Safety: Number of Participants With Systemic Adverse Reaction (Excluding Infections)

    Adverse reaction was defined as any TEAE that meets any of the following criteria: 1) A TEAE considered by either the investigator and/or the sponsor to be possibly or probably related to IP administration, or; 2) A TEAE that begins during infusion of IP or within 72 hours following the end of IP infusion, or; 3) A TEAE for which causality assessment is missing or indeterminate. Number of participants with systemic adverse reaction (excluding infections) was reported.

    Time frame: From start of study drug administration up to 20 months

  15. Safety: Rate of Systemic Adverse Reaction Per Infusion (Excluding Infections)

    Rate of Systemic adverse reactions per infusion was calculated as number of systemic adverse reaction events/total number of infusions administered to participants in the analysis set. Rate of systemic adverse reactions per infusion (excluding infections) was reported.

    Time frame: From start of study drug administration up to 20 months

  16. Safety: Number of Participants With Any TEAEs (Excluding Infections)

    TEAEs were the AEs with onset after date-time of first dose of IP, or any medical condition present prior to the start of IP but increased in severity or relationship after date-time of first dose of IP. Number of participants with any TEAEs (excluding infections) was reported.

    Time frame: From start of study drug administration up to 20 months

  17. Safety: Rate of TEAEs Per Infusion (Excluding Infections)

    Rate of TEAEs per infusion was calculated as number of adverse events/total number of infusions administered to participants in the analysis set. Rate of TEAEs per infusion (excluding infections) was reported.

    Time frame: From start of study drug administration up to 20 months

  18. Safety: Number of Participants With Any Adverse Reactions (Excluding Infections)

    Adverse reaction was defined as any TEAE that meets any of the following criteria: 1) A TEAE considered by either the investigator and/or the sponsor to be possibly or probably related to IP administration, or; 2) A TEAE that begins during infusion of IP or within 72 hours following the end of IP infusion, or; 3) A TEAE for which causality assessment is missing or indeterminate. Number of participants with any adverse reactions (excluding infections) was reported.

    Time frame: From start of study drug administration up to 20 months

  19. Safety: Rate of Any Adverse Reaction Per Infusion (Excluding Infections)

    Rate of all adverse reactions per infusion was calculated as number of adverse reaction events/total number of infusions administered to participants in the analysis set. Rate of any adverse reactions per infusion (excluding infections) was reported.

    Time frame: From start of study drug administration up to 20 months

  20. Safety: Number of Participants With Any Temporally Associated TEAEs (Excluding Infections)

    Temporally-associated TEAEs were defined as TEAEs which begin during infusion of IP or within 72 hours following the end of IP infusion. Number of participants with any temporally associated TEAEs (excluding infections) was reported.

    Time frame: From start of study drug administration up to 20 months

  21. Safety: Rate of Any Temporally Associated TEAEs Per Infusion (Excluding Infections)

    Rate of any temporally associated TEAEs per infusion was calculated as number of temporally associated adverse events/total number of infusions administered to participants in the analysis set. Temporally-associated TEAEs were defined as TEAEs which begin during infusion of IP or within 72 hours following the end of IP infusion. Rate of any temporally associated TEAEs per infusion (excluding infections) was reported.

    Time frame: From start of study drug administration up to 20 months

  22. Safety: Number of Participants With Any Related (Causally) and/or Temporally Associated TEAEs (Excluding Infections)

    Number of participants with any related (causally) and/or temporally associated TEAEs (excluding infections) was reported. Temporally-associated TEAEs were defined as TEAEs which begin during infusion of IP or within 72 hours following the end of IP infusion.

    Time frame: From start of study drug administration up to 20 months

  23. Safety: Rate of Any Related (Causally) and/or Temporally Associated TEAEs Per Infusion (Excluding Infections)

    Rate of any related (causally) and/or temporally associated TEAEs per infusion was calculated as number of related and/or temporally associated adverse events/ total number of infusions administered to participants in the analysis set. TEAEs recorded in the study database as "possibly related" or "probably related" to HYQVIA are considered HYQVIA-related adverse events. Temporally-associated TEAEs were defined as TEAEs which begin during infusion of IP or within 72 hours following the end of IP infusion. Rate of any related (causally) and/or temporally associated TEAEs per infusion (excluding infections) was reported.

    Time frame: From start of study drug administration up to 20 months

  24. Safety: Number of Participants With Any Serious TEAEs (Excluding Infections)

    Serious TEAE were the AEs that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged in-patient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Number of participants with any serious TEAEs (excluding infections) was reported.

    Time frame: From start of study drug administration up to 20 months

  25. Safety: Rate of Serious TEAEs Per Infusion (Excluding Infections)

    Rate of serious TEAEs per infusion was calculated as number of serious adverse events/total number of infusions administered to participants in the analysis set. Rate of serious TEAEs per infusion (excluding infections) was reported.

    Time frame: From start of study drug administration up to 20 months

  26. Safety: Number of Participants Who Developed Positive Titer (>=160) of Binding or Neutralizing Antibodies to rHuPH20

    Number of participants who developed positive titer (\>=160) of binding or neutralizing antibodies to rHuPH20 was reported.

    Time frame: From start of study drug administration up to 20 months

  27. Other Analysis: Number of Infusions Per Month

    Number of infusions per month was calculated as total number of infusions per duration of treatment (days) \* 30.4 days per month.

    Time frame: Up to 20 months

  28. Other Analysis: Number of Infusion Sites (Needle-Sticks) Per Infusion

    Number of infusion sites (needle-sticks) per infusion was calculated as total number of infusion sites / total number of infusions. Only infusions with complete data available were included.

    Time frame: Up to 20 months

  29. Other Analysis: Number of Infusion Sites (Needle-Sticks) Per Month

    Number of infusion sites per month was calculated as total number of infusion sites / duration of treatment (days) \* 30.4 days. Only infusions with complete data available were included.

    Time frame: Up to 20 months

  30. Other Analysis: Duration of Infusion

    The duration of infusion was defined as the difference between the end time and the start time of the HyQvia infusion.

    Time frame: From start of study drug administration up to 20 months.

  31. Other Analysis: Maximum Infusion Rate Per Site

    Maximum infusion rate per site was reported.

    Time frame: Up to 20 months

  32. Other Analysis: Infusion Volume Per Site

    Infusion volume per site was calculated as actual IgG volume (milliliter \[mL\]) / total number of infusion sites (hour) used.

    Time frame: Up to 20 months

  33. Other Analysis: Number of Infusions That Were Interrupted or Stopped Due to an AE

    Number of infusions that were interrupted or Stopped due to an AE was reported.

    Time frame: Up to 20 months

  34. Other Analysis: Number of Weeks to Reach Final 3 or 4-week Dose Interval in Epoch 1

    Final dose interval, defined as three or four weeks infusion interval in Epoch 1 of treatment period, was reported.

    Time frame: Up to 20 months

  35. Health Related Quality of Life (HR QoL): Change From Baseline in Pediatric Quality of Life Questionnaire (PedsQL)

    PedsQL Generic Core Scale (GCS) was used for QOL assessment. It encompasses 4 dimensions (physical functioning \[PF\], emotional functioning \[EF\], social functioning \[SF\], school functioning \[ScF\]). Age groups are: Toddler (2-4 years), Young child (5-7 years), Child (8-12 years), and Teens (13-\<18 years). Depending on the participants age, the questionnaire may be completed by either the participant or the parent/caregiver as appropriate. For the Toddler group, the PedsQL GCS consisted of 21 items, using a 5-point Likert scale (0 to 4); for all other groups, the PedsQL consisted of 23 items, with a 3-point Likert scale (0, 2, 4) for the young child, and a 5-point Likert scale for the child and teens groups. All Scores were transformed on a scale from 0 to 100 where 0=100, 1=75, 2=50, 3=25, and 4=0. Higher scores indicate better quality of life. A negative change from baseline indicates worse quality of life. Baseline: last non-missing value before the initial dose of HYQVIA.

    Time frame: Baseline up to 20 months

  36. HRQoL: Change From Baseline in EuroQoL (Quality of Life)-5 Dimensions (EQ-5D)

    EQ-5D considered five attributes of quality of life evaluation, that is, mobility, self-care, usual activity, pain/discomfort, and anxiety/depression. Each dimension had five possible levels: 1 (no problems); 2 (slight problems); 3 (moderate problems); 4 (severe problems), and; 5 (extreme problems). The participants rating of their current HRQoL state was recorded using a standard vertical 20-cm visual analog scale (EQ-VAS), which ranged from 0 to 100, where 0 indicated worst imaginable health state and 100 was best imaginable health state. Baseline was defined as the last non-missing value before the initial dose of HYQVIA. A negative change from baseline indicates worse health state.

    Time frame: Baseline up to 20 months

  37. HR QoL: Change From Baseline in Treatment Satisfaction Questionnaire for Medication-9 (TSQM-9)

    TSQM-9 is a 9-item, validated, self-administered instrument to assess participants satisfaction with medication. It consists of 3 subscales: effectiveness, convenience and global satisfaction. The scores were computed by adding items for each domain, i.e. 1 to 3 for effectiveness, 4 - 6 for convenience and 7 to 9 for global satisfaction. The lowest possible score (1 for each item and 3 for all 3 subscales) was subtracted from the composite score and divided by the greatest possible score range. The greatest range was (7-1)\*3 items = 18 for the effectiveness and convenience, and (5-1)\*3 items = 12 for global satisfaction . The item scores of each of the 3 domains are summed and transformed to create a score of 0 (extremely dissatisfied) to 100 (extremely satisfied). Higher score indicated greater satisfaction in that domain. A negative change from baseline indicates less satisfaction in that domain. Baseline was defined as the last non-missing value before the initial dose of HYQVIA.

    Time frame: Baseline up to 20 months

07

Results

Posted Jan 11, 2023

Participant flow

The study was conducted at 16 sites from 30 May 2017 to 15 January 2021. A total of 42 participants were enrolled and treated in this study. This study consisted of 3 treatment periods: Epoch 1, Epoch 2 and Epoch 3. Participant with anti-rHuPH20 antibody titer greater than or equal to (\>=) 160 during Epoch 1 or Epoch 2 and who experienced either a related serious adverse event or related severe adverse event were followed to Epoch 3.

Participant flow — Overall Study
MilestoneHyQvia New StartersHyQvia Pre-treated
Started2319
Started epoch 1230
Completed epoch 1220
Started epoch 22219
Completed epoch 22217
Moved from epoch 2 to epoch 310
Completed epoch 310
Completed2217
Not completed12
Withdrew: Withdrawal by subject12

Outcome measures

PrimarySafety: Number of Participants With Any Severe Related Treatment-emergent Adverse Events (TEAEs) Per Infusion (Excluding Infections)

An Adverse Event (AE) was defined as any untoward medical occurrence in a participant administered an investigational product (IP) that does not necessarily have a causal relationship with the treatment. TEAEs were the AEs with onset after date-time of first dose of IP, or any medical condition present prior to the start of IP but increased in severity or relationship after date-time of first dose of IP. TEAEs that were recorded as "possibly related" or "probably related" to HYQVIA were considered HYQVIA-related adverse events. Number of participants with any severe related TEAEs (excluding infections) was reported.

Time frame:
From start of study drug administration up to 20 months
Reported as:
Count of participants · Participants
Safety: Number of Participants With Any Severe Related Treatment-emergent Adverse Events (TEAEs) Per Infusion (Excluding Infections)
ParticipantsHyQvia New StartersHyQvia Pre-treated
Safety: Number of Participants With Any Severe Related Treatment-emergent Adverse Events (TEAEs) Per Infusion (Excluding Infections)10
PrimarySafety: Rate of Any Severe Related TEAEs Per Infusion (Excluding Infections)

An AE was defined as any untoward medical occurrence in a participant administered an IP that does not necessarily have a causal relationship with the treatment. TEAEs were the AEs with onset after date-time of first dose of IP, or any medical condition present prior to the start of IP but increased in severity or relationship after date-time of first dose of IP. TEAEs that were recorded as "possibly related" or "probably related" to HYQVIA were considered HYQVIA-related adverse events. Severe related TEAEs rate per infusion was calculated as number of severe related TEAEs/total number of infusions administered to participants in the analysis set. Rate of any severe related TEAEs per infusion (excluding infections) was reported.

Time frame:
From start of study drug administration up to 20 months
Reported as:
Number · Number of Severe Related TEAEs/Infusion
Safety: Rate of Any Severe Related TEAEs Per Infusion (Excluding Infections)
Number of Severe Related TEAEs/InfusionHyQvia New StartersHyQvia Pre-treated
Safety: Rate of Any Severe Related TEAEs Per Infusion (Excluding Infections)0.0040
PrimarySafety: Number of Participants With Any Related Serious TEAEs Per Infusion (Excluding Infections)

TEAEs were the AEs with onset after date-time of first dose of IP, or any medical condition present prior to the start of IP but increased in severity or relationship after date-time of first dose of IP. A serious TEAE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs that were recorded as "possibly related" or "probably related" to HYQVIA were considered HYQVIA-related adverse events. Number of participants with any related serious TEAEs per infusion (excluding infections) was reported.

Time frame:
From start of study drug administration up to 20 months
Reported as:
Count of participants · Participants
Safety: Number of Participants With Any Related Serious TEAEs Per Infusion (Excluding Infections)
ParticipantsHyQvia New StartersHyQvia Pre-treated
Safety: Number of Participants With Any Related Serious TEAEs Per Infusion (Excluding Infections)00
PrimarySafety: Rate of Any Related Serious TEAEs Per Infusion (Excluding Infections)

TEAEs were the AEs with onset after date-time of first dose of IP, or any medical condition present prior to the start of IP but increased in severity or relationship after date-time of first dose of IP. A serious TEAE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged in-patient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs that were recorded as "possibly related" or "probably related" to HYQVIA were considered HYQVIA-related adverse events. Rate of related serious TEAEs per infusion was calculated as number of related serious TEAEs/total number of infusions administered to participants in the analysis set. Rate of any related serious TEAEs per Infusion (excluding infections) was reported.

Time frame:
From start of study drug administration up to 20 months
Reported as:
Number · Number of Related Serious TEAEs/Infusion
Safety: Rate of Any Related Serious TEAEs Per Infusion (Excluding Infections)
Number of Related Serious TEAEs/InfusionHyQvia New StartersHyQvia Pre-treated
Safety: Rate of Any Related Serious TEAEs Per Infusion (Excluding Infections)00
SecondaryEfficacy: Change From Baseline in Total Serum Trough Levels of Immunoglobulin G (IgG) at Month 12

Change from baseline in total serum trough levels of IgG in Epoch 1 and 2 was reported. Baseline was defined as the last non-missing value before the initial dose of HYQVIA.

Time frame:
Baseline, Month 12
Reported as:
Mean · Gram per liter (g/L)
Efficacy: Change From Baseline in Total Serum Trough Levels of Immunoglobulin G (IgG) at Month 12
Gram per liter (g/L)HyQvia New StartersHyQvia Pre-treated
Efficacy: Change From Baseline in Total Serum Trough Levels of Immunoglobulin G (IgG) at Month 120.035 ± 1.6983-0.709 ± 2.6576
SecondaryEfficacy: Change From Baseline in Serum Trough Levels of IgG Subclasses at Month 12

Change from baseline in Serum trough levels of IgG subclasses 1, 2, 3, and 4 in Epoch 1 and 2 was reported. Baseline was defined as the last non-missing value before the initial dose of HYQVIA.

Time frame:
Baseline, Month 12
Reported as:
Mean · g/L
Efficacy: Change From Baseline in Serum Trough Levels of IgG Subclasses at Month 12
g/LHyQvia New StartersHyQvia Pre-treated
IgG Subclass 1 : Changed at Month 12-0.813 ± 1.1087-0.467 ± 1.5976
IgG Subclass 2 : Changed at Month 120.000 ± 0.8944-0.667 ± 1.3452
IgG Subclass 3 : Changed at Month 120.000 ± 0.36510.133 ± 0.3519
IgG Subclass 4 : Changed at Month 120.094 ± 0.0854-0.027 ± 0.0799
SecondaryEfficacy: Change From Baseline in Trough Levels of Specific Antibodies to Clostridium Tetani Toxoid IgG at Month 12

Change from baseline in trough levels of specific antibodies in clostridium tetani toxoid IgG at Month 12 was reported. Baseline was defined as the last non-missing value before the initial dose of HYQVIA. Here, IU/ml was defined as "International units per milliliter".

Time frame:
Baseline, Month 12
Reported as:
Mean · IU/ml
Efficacy: Change From Baseline in Trough Levels of Specific Antibodies to Clostridium Tetani Toxoid IgG at Month 12
IU/mlHyQvia New StartersHyQvia Pre-treated
Efficacy: Change From Baseline in Trough Levels of Specific Antibodies to Clostridium Tetani Toxoid IgG at Month 12-0.218 ± 0.9345—
SecondaryEfficacy: Change From Baseline in Trough Levels of Specific Antibodies to Hepatitis B Virus (HBV) at Month 12

Change from baseline in trough levels of specific antibodies in HBV at Month 12 was reported. Baseline was defined as the last non-missing value before the initial dose of HYQVIA.

Time frame:
Baseline, Month 12
Reported as:
Mean · International units per liter (IU/L)
Efficacy: Change From Baseline in Trough Levels of Specific Antibodies to Hepatitis B Virus (HBV) at Month 12
International units per liter (IU/L)HyQvia New StartersHyQvia Pre-treated
Efficacy: Change From Baseline in Trough Levels of Specific Antibodies to Hepatitis B Virus (HBV) at Month 12167.875 ± 147.4887—
SecondaryEfficacy: Change From Baseline in Trough Levels of Specific Antibodies to Haemophilus Influenzae B IgG at Month 12

Change from baseline in trough levels of specific antibodies in Haemophilus influenzae B IgG at Month 12 was reported. Baseline was defined as the last non-missing value before the initial dose of HYQVIA.

Time frame:
Baseline, Month 12
Reported as:
Mean · Milligram per liter (mg/L)
Efficacy: Change From Baseline in Trough Levels of Specific Antibodies to Haemophilus Influenzae B IgG at Month 12
Milligram per liter (mg/L)HyQvia New StartersHyQvia Pre-treated
Efficacy: Change From Baseline in Trough Levels of Specific Antibodies to Haemophilus Influenzae B IgG at Month 12-0.017 ± 0.9503—
SecondarySafety: Percentage of Participants Who Achieved a Treatment Interval of Three or Four Weeks in Epoch 2

Percentage of participants who achieved a treatment interval of three or four weeks in Epoch 2 was reported.

Time frame:
Up to 20 months
Reported as:
Number · Percentage of participants
Safety: Percentage of Participants Who Achieved a Treatment Interval of Three or Four Weeks in Epoch 2
Percentage of participantsHyQvia New StartersHyQvia Pre-treated
Every 3 weeks treatment interval39.115.8
Every 4 weeks treatment interval60.984.2
SecondarySafety: Percentage of Participants Who Maintained a Treatment Interval of Three or Four Weeks in Epoch 2 up to 12 Months

Percentage of participants who maintained a treatment interval of three or four weeks in Epoch 2 up to 12 months was reported.

Time frame:
Up to 12 months
Reported as:
Number · Percentage of participants
Safety: Percentage of Participants Who Maintained a Treatment Interval of Three or Four Weeks in Epoch 2 up to 12 Months
Percentage of participantsHyQvia New StartersHyQvia Pre-treated
Safety: Percentage of Participants Who Maintained a Treatment Interval of Three or Four Weeks in Epoch 2 up to 12 Months87.078.9
SecondarySafety: Number of Participants With Local TEAEs (Excluding Infections)

TEAEs were the AEs with onset after date-time of first dose of IP, or any medical condition present prior to the start of IP but increased in severity or relationship after date-time of first dose of IP. Number of Participants with local TEAEs (excluding infections) was reported.

Time frame:
From start of study drug administration up to 20 months
Reported as:
Count of participants · Participants
Safety: Number of Participants With Local TEAEs (Excluding Infections)
ParticipantsHyQvia New StartersHyQvia Pre-treated
Safety: Number of Participants With Local TEAEs (Excluding Infections)113
SecondarySafety: Rate of Local TEAEs Per Infusion (Excluding Infections)

Rate of local TEAEs per infusion was calculated as number of local adverse events/total number of infusions administered to participants in the analysis set. Only events are included which start prior to participants start date of non-response. Rate of local TEAEs per infusion (excluding infections) was reported.

Time frame:
From start of study drug administration up to 20 months
Reported as:
Number · Number of local TEAEs/Infusion
Safety: Rate of Local TEAEs Per Infusion (Excluding Infections)
Number of local TEAEs/InfusionHyQvia New StartersHyQvia Pre-treated
Safety: Rate of Local TEAEs Per Infusion (Excluding Infections)0.0820.009
SecondarySafety: Number of Participants With Local Adverse Reaction (Excluding Infections)

Adverse reaction was defined as any TEAE that meets any of the following criteria: 1) A TEAE considered by either the investigator and/or the sponsor to be possibly or probably related to IP administration, or; 2) A TEAE that begins during infusion of IP or within 72 hours following the end of IP infusion, or; 3) A TEAE for which causality assessment is missing or indeterminate. Number of participants with local adverse reactions (excluding infections) was reported.

Time frame:
From start of study drug administration up to 20 months
Reported as:
Count of participants · Participants
Safety: Number of Participants With Local Adverse Reaction (Excluding Infections)
ParticipantsHyQvia New StartersHyQvia Pre-treated
Safety: Number of Participants With Local Adverse Reaction (Excluding Infections)113
SecondarySafety: Rate of Local Adverse Reaction Per Infusion (Excluding Infections)

Rate of local adverse reaction per infusion was calculated as number of local adverse reaction events/total number of infusions administered to participants in the analysis set. Rate of local adverse reactions per infusion (excluding infections) was reported.

Time frame:
From start of study drug administration up to 20 months
Reported as:
Number · Number of Local AR events/Infusion
Safety: Rate of Local Adverse Reaction Per Infusion (Excluding Infections)
Number of Local AR events/InfusionHyQvia New StartersHyQvia Pre-treated
Safety: Rate of Local Adverse Reaction Per Infusion (Excluding Infections)0.0800.009
SecondarySafety: Number of Participants With Systemic TEAEs (Excluding Infections)

TEAEs were the AEs with onset after date-time of first dose of IP, or any medical condition present prior to the start of IP but increased in severity or relationship after date-time of first dose of IP. Number of participants with systemic TEAEs (excluding infections) was reported..

Time frame:
From start of study drug administration up to 20 months
Reported as:
Count of participants · Participants
Safety: Number of Participants With Systemic TEAEs (Excluding Infections)
ParticipantsHyQvia New StartersHyQvia Pre-treated
Safety: Number of Participants With Systemic TEAEs (Excluding Infections)1510
SecondarySafety: Rate of Systemic TEAEs Per Infusion (Excluding Infections)

Rate of systemic TEAEs per infusion was calculated as number of systemic adverse events/total number of infusions administered to participants in the analysis set. Rate of systemic TEAEs per infusion was assessed based on events per infusion.

Time frame:
From start of study drug administration up to 20 months
Reported as:
Number · Number of systemic TEAEs/Infusion
Safety: Rate of Systemic TEAEs Per Infusion (Excluding Infections)
Number of systemic TEAEs/InfusionHyQvia New StartersHyQvia Pre-treated
Safety: Rate of Systemic TEAEs Per Infusion (Excluding Infections)0.1380.142
SecondarySafety: Number of Participants With Systemic Adverse Reaction (Excluding Infections)

Adverse reaction was defined as any TEAE that meets any of the following criteria: 1) A TEAE considered by either the investigator and/or the sponsor to be possibly or probably related to IP administration, or; 2) A TEAE that begins during infusion of IP or within 72 hours following the end of IP infusion, or; 3) A TEAE for which causality assessment is missing or indeterminate. Number of participants with systemic adverse reaction (excluding infections) was reported.

Time frame:
From start of study drug administration up to 20 months
Reported as:
Count of participants · Participants
Safety: Number of Participants With Systemic Adverse Reaction (Excluding Infections)
ParticipantsHyQvia New StartersHyQvia Pre-treated
Safety: Number of Participants With Systemic Adverse Reaction (Excluding Infections)31
SecondarySafety: Rate of Systemic Adverse Reaction Per Infusion (Excluding Infections)

Rate of Systemic adverse reactions per infusion was calculated as number of systemic adverse reaction events/total number of infusions administered to participants in the analysis set. Rate of systemic adverse reactions per infusion (excluding infections) was reported.

Time frame:
From start of study drug administration up to 20 months
Reported as:
Number · Number of systemic AR events/Infusion
Safety: Rate of Systemic Adverse Reaction Per Infusion (Excluding Infections)
Number of systemic AR events/InfusionHyQvia New StartersHyQvia Pre-treated
Safety: Rate of Systemic Adverse Reaction Per Infusion (Excluding Infections)0.0110.012
SecondarySafety: Number of Participants With Any TEAEs (Excluding Infections)

TEAEs were the AEs with onset after date-time of first dose of IP, or any medical condition present prior to the start of IP but increased in severity or relationship after date-time of first dose of IP. Number of participants with any TEAEs (excluding infections) was reported.

Time frame:
From start of study drug administration up to 20 months
Reported as:
Count of participants · Participants
Safety: Number of Participants With Any TEAEs (Excluding Infections)
ParticipantsHyQvia New StartersHyQvia Pre-treated
Safety: Number of Participants With Any TEAEs (Excluding Infections)1811
SecondarySafety: Rate of TEAEs Per Infusion (Excluding Infections)

Rate of TEAEs per infusion was calculated as number of adverse events/total number of infusions administered to participants in the analysis set. Rate of TEAEs per infusion (excluding infections) was reported.

Time frame:
From start of study drug administration up to 20 months
Reported as:
Number · Number of TEAEs/Infusion
Safety: Rate of TEAEs Per Infusion (Excluding Infections)
Number of TEAEs/InfusionHyQvia New StartersHyQvia Pre-treated
Safety: Rate of TEAEs Per Infusion (Excluding Infections)0.2200.151
SecondarySafety: Number of Participants With Any Adverse Reactions (Excluding Infections)

Adverse reaction was defined as any TEAE that meets any of the following criteria: 1) A TEAE considered by either the investigator and/or the sponsor to be possibly or probably related to IP administration, or; 2) A TEAE that begins during infusion of IP or within 72 hours following the end of IP infusion, or; 3) A TEAE for which causality assessment is missing or indeterminate. Number of participants with any adverse reactions (excluding infections) was reported.

Time frame:
From start of study drug administration up to 20 months
Reported as:
Count of participants · Participants
Safety: Number of Participants With Any Adverse Reactions (Excluding Infections)
ParticipantsHyQvia New StartersHyQvia Pre-treated
Safety: Number of Participants With Any Adverse Reactions (Excluding Infections)123
SecondarySafety: Rate of Any Adverse Reaction Per Infusion (Excluding Infections)

Rate of all adverse reactions per infusion was calculated as number of adverse reaction events/total number of infusions administered to participants in the analysis set. Rate of any adverse reactions per infusion (excluding infections) was reported.

Time frame:
From start of study drug administration up to 20 months
Reported as:
Number · Adverse reaction event/Infusion
Safety: Rate of Any Adverse Reaction Per Infusion (Excluding Infections)
Adverse reaction event/InfusionHyQvia New StartersHyQvia Pre-treated
Safety: Rate of Any Adverse Reaction Per Infusion (Excluding Infections)0.0910.021
SecondarySafety: Number of Participants With Any Temporally Associated TEAEs (Excluding Infections)

Temporally-associated TEAEs were defined as TEAEs which begin during infusion of IP or within 72 hours following the end of IP infusion. Number of participants with any temporally associated TEAEs (excluding infections) was reported.

Time frame:
From start of study drug administration up to 20 months
Reported as:
Count of participants · Participants
Safety: Number of Participants With Any Temporally Associated TEAEs (Excluding Infections)
ParticipantsHyQvia New StartersHyQvia Pre-treated
Safety: Number of Participants With Any Temporally Associated TEAEs (Excluding Infections)136
SecondarySafety: Rate of Any Temporally Associated TEAEs Per Infusion (Excluding Infections)

Rate of any temporally associated TEAEs per infusion was calculated as number of temporally associated adverse events/total number of infusions administered to participants in the analysis set. Temporally-associated TEAEs were defined as TEAEs which begin during infusion of IP or within 72 hours following the end of IP infusion. Rate of any temporally associated TEAEs per infusion (excluding infections) was reported.

Time frame:
From start of study drug administration up to 20 months
Reported as:
Number · Temporally associated TEAEs/Infusion
Safety: Rate of Any Temporally Associated TEAEs Per Infusion (Excluding Infections)
Temporally associated TEAEs/InfusionHyQvia New StartersHyQvia Pre-treated
Safety: Rate of Any Temporally Associated TEAEs Per Infusion (Excluding Infections)0.1060.027
SecondarySafety: Number of Participants With Any Related (Causally) and/or Temporally Associated TEAEs (Excluding Infections)

Number of participants with any related (causally) and/or temporally associated TEAEs (excluding infections) was reported. Temporally-associated TEAEs were defined as TEAEs which begin during infusion of IP or within 72 hours following the end of IP infusion.

Time frame:
From start of study drug administration up to 20 months
Reported as:
Count of participants · Participants
Safety: Number of Participants With Any Related (Causally) and/or Temporally Associated TEAEs (Excluding Infections)
ParticipantsHyQvia New StartersHyQvia Pre-treated
Safety: Number of Participants With Any Related (Causally) and/or Temporally Associated TEAEs (Excluding Infections)136
SecondarySafety: Rate of Any Related (Causally) and/or Temporally Associated TEAEs Per Infusion (Excluding Infections)

Rate of any related (causally) and/or temporally associated TEAEs per infusion was calculated as number of related and/or temporally associated adverse events/ total number of infusions administered to participants in the analysis set. TEAEs recorded in the study database as "possibly related" or "probably related" to HYQVIA are considered HYQVIA-related adverse events. Temporally-associated TEAEs were defined as TEAEs which begin during infusion of IP or within 72 hours following the end of IP infusion. Rate of any related (causally) and/or temporally associated TEAEs per infusion (excluding infections) was reported.

Time frame:
From start of study drug administration up to 20 months
Reported as:
Number · Related Temporally TEAEs/Infusion
Safety: Rate of Any Related (Causally) and/or Temporally Associated TEAEs Per Infusion (Excluding Infections)
Related Temporally TEAEs/InfusionHyQvia New StartersHyQvia Pre-treated
Safety: Rate of Any Related (Causally) and/or Temporally Associated TEAEs Per Infusion (Excluding Infections)0.1120.033
SecondarySafety: Number of Participants With Any Serious TEAEs (Excluding Infections)

Serious TEAE were the AEs that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged in-patient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Number of participants with any serious TEAEs (excluding infections) was reported.

Time frame:
From start of study drug administration up to 20 months
Reported as:
Count of participants · Participants
Safety: Number of Participants With Any Serious TEAEs (Excluding Infections)
ParticipantsHyQvia New StartersHyQvia Pre-treated
Safety: Number of Participants With Any Serious TEAEs (Excluding Infections)03
SecondarySafety: Rate of Serious TEAEs Per Infusion (Excluding Infections)

Rate of serious TEAEs per infusion was calculated as number of serious adverse events/total number of infusions administered to participants in the analysis set. Rate of serious TEAEs per infusion (excluding infections) was reported.

Time frame:
From start of study drug administration up to 20 months
Reported as:
Number · Number of serious TEAEs/Infusion
Safety: Rate of Serious TEAEs Per Infusion (Excluding Infections)
Number of serious TEAEs/InfusionHyQvia New StartersHyQvia Pre-treated
Safety: Rate of Serious TEAEs Per Infusion (Excluding Infections)00.012
SecondarySafety: Number of Participants Who Developed Positive Titer (>=160) of Binding or Neutralizing Antibodies to rHuPH20

Number of participants who developed positive titer (\>=160) of binding or neutralizing antibodies to rHuPH20 was reported.

Time frame:
From start of study drug administration up to 20 months
Reported as:
Count of participants · Participants
Safety: Number of Participants Who Developed Positive Titer (>=160) of Binding or Neutralizing Antibodies to rHuPH20
ParticipantsHyQvia New StartersHyQvia Pre-treated
Participants with positive titer (>=160) of binding antibodies00
Participants with neutralizing antibodies00
SecondaryOther Analysis: Number of Infusions Per Month

Number of infusions per month was calculated as total number of infusions per duration of treatment (days) \* 30.4 days per month.

Time frame:
Up to 20 months
Reported as:
Median · Infusion/Month
Other Analysis: Number of Infusions Per Month
Infusion/MonthHyQvia New StartersHyQvia Pre-treated
Other Analysis: Number of Infusions Per Month1.30 (1.1 to 1.7)1.20 (1.0 to 1.6)
SecondaryOther Analysis: Number of Infusion Sites (Needle-Sticks) Per Infusion

Number of infusion sites (needle-sticks) per infusion was calculated as total number of infusion sites / total number of infusions. Only infusions with complete data available were included.

Time frame:
Up to 20 months
Reported as:
Mean · Infusion sites (needle sticks)/Infusion
Other Analysis: Number of Infusion Sites (Needle-Sticks) Per Infusion
Infusion sites (needle sticks)/InfusionHyQvia New StartersHyQvia Pre-treated
Other Analysis: Number of Infusion Sites (Needle-Sticks) Per Infusion1.65 ± 0.4421.25 ± 0.403
SecondaryOther Analysis: Number of Infusion Sites (Needle-Sticks) Per Month

Number of infusion sites per month was calculated as total number of infusion sites / duration of treatment (days) \* 30.4 days. Only infusions with complete data available were included.

Time frame:
Up to 20 months
Reported as:
Mean · Infusion sites (needle sticks)/Month
Other Analysis: Number of Infusion Sites (Needle-Sticks) Per Month
Infusion sites (needle sticks)/MonthHyQvia New StartersHyQvia Pre-treated
Other Analysis: Number of Infusion Sites (Needle-Sticks) Per Month1.96 ± 0.7801.33 ± 0.634
SecondaryOther Analysis: Duration of Infusion

The duration of infusion was defined as the difference between the end time and the start time of the HyQvia infusion.

Time frame:
From start of study drug administration up to 20 months.
Reported as:
Median · Minutes
Other Analysis: Duration of Infusion
MinutesHyQvia New StartersHyQvia Pre-treated
Other Analysis: Duration of Infusion75.0 (10 to 215)101.0 (15 to 257)
SecondaryOther Analysis: Maximum Infusion Rate Per Site

Maximum infusion rate per site was reported.

Time frame:
Up to 20 months
Reported as:
Mean · Milliliter per hour per site (mL/h/site)
Other Analysis: Maximum Infusion Rate Per Site
Milliliter per hour per site (mL/h/site)HyQvia New StartersHyQvia Pre-treated
Other Analysis: Maximum Infusion Rate Per Site181.54 ± 77.772171.73 ± 90.203
SecondaryOther Analysis: Infusion Volume Per Site

Infusion volume per site was calculated as actual IgG volume (milliliter \[mL\]) / total number of infusion sites (hour) used.

Time frame:
Up to 20 months
Reported as:
Mean · Milliliter per hour
Other Analysis: Infusion Volume Per Site
Milliliter per hourHyQvia New StartersHyQvia Pre-treated
Other Analysis: Infusion Volume Per Site112.39 ± 71.427178.23 ± 98.523
SecondaryOther Analysis: Number of Infusions That Were Interrupted or Stopped Due to an AE

Number of infusions that were interrupted or Stopped due to an AE was reported.

Time frame:
Up to 20 months
Reported as:
Number · Infusions
Other Analysis: Number of Infusions That Were Interrupted or Stopped Due to an AE
InfusionsHyQvia New StartersHyQvia Pre-treated
Number of infusions interrupted40
Number of infusions Stopped10
SecondaryOther Analysis: Number of Weeks to Reach Final 3 or 4-week Dose Interval in Epoch 1

Final dose interval, defined as three or four weeks infusion interval in Epoch 1 of treatment period, was reported.

Time frame:
Up to 20 months
Reported as:
Median · Weeks
Other Analysis: Number of Weeks to Reach Final 3 or 4-week Dose Interval in Epoch 1
WeeksHyQvia New StartersHyQvia Pre-treated
Other Analysis: Number of Weeks to Reach Final 3 or 4-week Dose Interval in Epoch 16.10 (3.0 to 7.0)—
SecondaryHealth Related Quality of Life (HR QoL): Change From Baseline in Pediatric Quality of Life Questionnaire (PedsQL)

PedsQL Generic Core Scale (GCS) was used for QOL assessment. It encompasses 4 dimensions (physical functioning \[PF\], emotional functioning \[EF\], social functioning \[SF\], school functioning \[ScF\]). Age groups are: Toddler (2-4 years), Young child (5-7 years), Child (8-12 years), and Teens (13-\<18 years). Depending on the participants age, the questionnaire may be completed by either the participant or the parent/caregiver as appropriate. For the Toddler group, the PedsQL GCS consisted of 21 items, using a 5-point Likert scale (0 to 4); for all other groups, the PedsQL consisted of 23 items, with a 3-point Likert scale (0, 2, 4) for the young child, and a 5-point Likert scale for the child and teens groups. All Scores were transformed on a scale from 0 to 100 where 0=100, 1=75, 2=50, 3=25, and 4=0. Higher scores indicate better quality of life. A negative change from baseline indicates worse quality of life. Baseline: last non-missing value before the initial dose of HYQVIA.

Time frame:
Baseline up to 20 months
Reported as:
Mean · Score on a scale
Health Related Quality of Life (HR QoL): Change From Baseline in Pediatric Quality of Life Questionnaire (PedsQL)
Score on a scaleHyQvia New StartersHyQvia Pre-treated
PF in Toddler: Change up to 20 months—-3.12 ± NA
PF in Young child: Change up to 20 months—-31.25 ± NA
PF in Child: Change up to 20 months7.81 ± 6.626-71.88 ± NA
PF in Teens: Change up to 20 months-12.65 ± 12.72613.75 ± 24.664
EF in Toddler: Change up to 20 months—0.00 ± NA
EF in Young child: Change up to 20 months—-25.00 ± NA
EF in Child: Change up to 20 months5.00 ± 14.142-20.00 ± NA
EF in Teens: Change up to 20 months-13.33 ± 7.6381.25 ± 14.307
SF in Toddler: Change up to 20 months—0.00 ± NA
SF in Young child: Change up to 20 months—-35.00 ± NA
SF in Child: Change up to 20 months-20.00 ± 0.000-40.00 ± NA
SF in Teens: Change up to 20 months1.67 ± 7.6388.00 ± 11.511
ScF in Toddler: Change up to 20 months—25.00 ± NA
ScF in Young child: Change up to 20 months—-45.00 ± NA
ScF in Child: Change up to 20 months-12.50 ± 10.607-65.00 ± NA
ScF in Teens: Change up to 20 months1.67 ± 7.638-17.00 ± 24.135
SecondaryHRQoL: Change From Baseline in EuroQoL (Quality of Life)-5 Dimensions (EQ-5D)

EQ-5D considered five attributes of quality of life evaluation, that is, mobility, self-care, usual activity, pain/discomfort, and anxiety/depression. Each dimension had five possible levels: 1 (no problems); 2 (slight problems); 3 (moderate problems); 4 (severe problems), and; 5 (extreme problems). The participants rating of their current HRQoL state was recorded using a standard vertical 20-cm visual analog scale (EQ-VAS), which ranged from 0 to 100, where 0 indicated worst imaginable health state and 100 was best imaginable health state. Baseline was defined as the last non-missing value before the initial dose of HYQVIA. A negative change from baseline indicates worse health state.

Time frame:
Baseline up to 20 months
Reported as:
Mean · Score on a scale
HRQoL: Change From Baseline in EuroQoL (Quality of Life)-5 Dimensions (EQ-5D)
Score on a scaleHyQvia New StartersHyQvia Pre-treated
HRQoL: Change From Baseline in EuroQoL (Quality of Life)-5 Dimensions (EQ-5D)-8.60 ± 11.149-4.43 ± 15.447
SecondaryHR QoL: Change From Baseline in Treatment Satisfaction Questionnaire for Medication-9 (TSQM-9)

TSQM-9 is a 9-item, validated, self-administered instrument to assess participants satisfaction with medication. It consists of 3 subscales: effectiveness, convenience and global satisfaction. The scores were computed by adding items for each domain, i.e. 1 to 3 for effectiveness, 4 - 6 for convenience and 7 to 9 for global satisfaction. The lowest possible score (1 for each item and 3 for all 3 subscales) was subtracted from the composite score and divided by the greatest possible score range. The greatest range was (7-1)\*3 items = 18 for the effectiveness and convenience, and (5-1)\*3 items = 12 for global satisfaction . The item scores of each of the 3 domains are summed and transformed to create a score of 0 (extremely dissatisfied) to 100 (extremely satisfied). Higher score indicated greater satisfaction in that domain. A negative change from baseline indicates less satisfaction in that domain. Baseline was defined as the last non-missing value before the initial dose of HYQVIA.

Time frame:
Baseline up to 20 months
Reported as:
Mean · Score on a scale
HR QoL: Change From Baseline in Treatment Satisfaction Questionnaire for Medication-9 (TSQM-9)
Score on a scaleHyQvia New StartersHyQvia Pre-treated
Effectiveness: Change at 20 months12.96 ± 32.552-0.92 ± 10.783
Convenience: Change at 20 months14.81 ± 27.3984.63 ± 15.873
Global satisfaction: Change 20 months11.90 ± 10.911-2.38 ± 19.518

Adverse events

Collected over From start of study drug administration up to end of the study (up to 43 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
HyQvia New Starters0/23 (0%)2/23 (8.7%)22/23 (95.7%)
HyQvia Pre-treated0/19 (0%)5/19 (26.3%)14/19 (73.7%)
Most frequent serious events
Most frequent serious events
EventHyQvia New StartersHyQvia Pre-treated
Idiopathic orbital inflammationEye disorders0/231/19
Dental cariesGastrointestinal disorders0/231/19
Inflammatory bowel diseaseGastrointestinal disorders0/231/19
PyrexiaGeneral disorders0/231/19
Pilonidal cystInfections and infestations0/231/19
Acute sinusitisInfections and infestations0/231/19
PharyngitisInfections and infestations1/230/19
PneumoniaInfections and infestations1/230/19
Most frequent other events
Showing 10 of 41
Most frequent other events
EventHyQvia New StartersHyQvia Pre-treated
CoughRespiratory, thoracic and mediastinal disorders8/236/19
RhinitisInfections and infestations3/236/19
Infusion site painGeneral disorders6/231/19
GastroenteritisInfections and infestations5/230/19
NasopharyngitisInfections and infestations5/231/19
Infusion site pruritusGeneral disorders4/230/19
PyrexiaGeneral disorders3/233/19
Upper respiratory tract infectionInfections and infestations0/233/19
FatigueGeneral disorders3/231/19
Viral infectionInfections and infestations3/230/19

Baseline characteristics

Safety analysis set included all participants in the full analysis set (enrolled set) who received at least one dose of HyQvia.

Age, Continuous
Age, Continuous(Years)HyQvia New StartersHyQvia Pre-treatedTotal
Mean10.3 ± 3.8211.7 ± 4.3311 ± 4.07
Sex: Female, Male
Sex: Female, Male(Participants)HyQvia New StartersHyQvia Pre-treatedTotal
Female538
Male181634
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)HyQvia New StartersHyQvia Pre-treatedTotal
Hispanic or Latino000
Not Hispanic or Latino231942
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)HyQvia New StartersHyQvia Pre-treatedTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White221941
More than one race000
Unknown or Not Reported101
08

Study locations

20 sites
  • Fakultni nemocnice Brno Odd. Detska klinika
    Brno, 61300, Czechia
  • Fakultní nemocnice Hradec Králové
    Nový Hradec Králové, 500 05, Czechia
  • FN v Motole Interni klinika
    Prague, 15006, Czechia
  • Rigshospitalet
    København, 2100, Denmark
  • Groupe Hospitalier Pellegrin - Hôpital des Enfants
    Bordeaux, Gironde 33076, France
  • CHU Angers - Hôpital Hôtel Dieu
    Angers, 49033, France
  • Hospices Civils de Lyon - Hôpitaux Est - IHOP
    Lyon, 69008, France
  • Agia Sophia Children's Hospital
    Athens, 115 27, Greece
  • General Hospital of Thessaloniki Ippokrateio
    Thessaloniki, 546 42, Greece
  • General Hospital of Thessaloniki Papageorgiou
    Thessaloniki, 564 03, Greece
  • United St. Istvan and St. Laszlo Hospital
    Budapest, H-1097, Hungary
  • 1.Detská klinika
    Bratislava, 83340, Slovakia
  • Univerzitna Nemocnica Klinika detí a dorastu
    Martin, 03659, Slovakia
  • Queen Silvia Children's Hospital
    Goteborg, 416 85, Sweden
  • Dept. of Pediatric Oncology/Hematology/Immunology-Skånes Universitetssjukhus
    Lund, 221 85, Sweden
  • Bristol Royal Hospital for Children
    Bristol, Avon BS2 8BJ, United Kingdom
  • Leeds Children's Hospital
    Leeds, West Yorkshire LS1 3EX, United Kingdom
  • Royal Victoria Hospital
    Belfast, BT1 6DW, United Kingdom
  • University Hospital of Wales Heath Park Clinical Research Facility
    Cardiff, CF14 4XW, United Kingdom
  • The Great North Children's Hospital Royal Victoria Infirmary
    Newcastle upon Tyne, NE7 7DN, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2017 to primary completion in Jan 2021, 43 months.

Results were first posted in Jan 2023, 1 year 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2017
First posted
Apr 17, 2017
StartActual
May 30, 2017
Primary completionActual
Jan 15, 2021
CompletionActual
Jan 15, 2021
Results first posted
Jan 11, 2023
Last update
Jan 11, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 11, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03116347
Collaborators
Baxalta Innovations GmbH, now part of Shire
Responsible party
Sponsor
First posted
Apr 17, 2017
Start date
May 30, 2017
Primary completion
Jan 15, 2021
Completion
Jan 15, 2021
Results posted
Jan 11, 2023
Last update
Jan 11, 2023

Study contacts

Study Director
study director · Shire

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Immunoglobulin G · Hyaluronoglucosaminidase · Immunoglobulins, Intravenous

Start the discussion